Personalized risk estimates for children with newly diagnosed JIA
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study looks at how best to estimate a child’s likely symptoms and treatment response in the first phase after a new JIA diagnosis. It may help families and clinicians make clearer, more personalized decisions about care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child has JIA and was diagnosed within the last month
- Your child has not started treatment yet, or has only used anti-inflammatory pain medicines (NSAIDs) or joint injections
- Your child’s JIA is not the “systemic arthritis” type
- You can complete study forms and questionnaires in English or French
- You agree to extra questionnaires about decision-making
- You agree your visit may be recorded if chosen by chance
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study creates a personalized medicine network to better understand and treat childhood arthritis. If you have JIA or unexplained joint inflammation, researchers will look at your biology to find the best treatment approach for you.
This trial tests whether children with juvenile idiopathic arthritis (JIA) who have been doing well for over a year can safely reduce their medications. The goal is to find the best way to keep arthritis under control while avoiding unnecessary treatments.
This study tests an online self-management program for teens with newly diagnosed JIA. It helps you learn skills to manage your condition, connect with others, and feel more in control.
This trial studies sarilumab, a targeted medicine, to help reduce symptoms in children and teens with systemic juvenile idiopathic arthritis (sJIA) who have not responded enough to current treatments. You may be considered because the study looks at how well and safely repeated doses work in pediatric patients.
This Phase 3 trial studies how well upadacitinib (a pill) and tocilizumab (a shot/IV medicine) improve symptoms and inflammation in children with active systemic juvenile idiopathic arthritis (sJIA). It also looks at side effects and how these medicines move through the body.
This study looks at how to measure treatment success in children with juvenile idiopathic arthritis (JIA), lupus (SLE), or fibromyalgia (FM). It may help doctors track symptoms more reliably over time.
Hear when a new Juvenile Idiopathic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.